Literature DB >> 23539726

First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.

David Taïeb1, Chunzhang Yang, Blandine Delenne, Zhengping Zhuang, Anne Barlier, Fréderic Sebag, Karel Pacak.   

Abstract

CONTEXT: Molecular genetic research has so far resulted in the identification of 10 well-characterized susceptibility genes for hereditary pheochromocytoma (PHEO) or paraganglioma (PGL). Recently, a new syndrome characterized by multiple PGLs and somatostatinomas associated with congenital polycythemia due to somatic mutations in HIF2A has been reported.
OBJECTIVE: The aim of the study was to define the genetic defect in a new case of bilateral PHEO and multiple PGLs associated with congenital polycythemia. PATIENT: A female patient presented with neonatal polycythemia (treated by phlebotomies, 1 session approximately every 4 mo), mildly enlarged cerebral ventricles, and bilateral PHEO and multiple PGLs. There was no family history of any neuroendocrine tumor or polycythemia. Surgical removal of the tumors only temporarily normalized plasma erythropoietin (Epo) levels and discontinued phlebotomies. No germline mutations were initially detected in the SDHB, SDHC, SDHD, VHL, and PHD2 genes, known to be associated with polycythemia. The PHEOs presented with a typical noradrenergic biochemical phenotype.
RESULTS: A heterozygous missense mutation (c.1589C>T) was identified in exon 12 of HIF2A, resulting in an alanine 530 substitution in the HIF-2α protein with valine (A530V). This somatic mutation was detected in the tissue from 1 PHEO and 1 PGL, with no HIF2A germline mutation found. This mutation led to stabilization of HIF-2α and hence a gain-of-function phenotype, as in previously published studies.
CONCLUSION: This case represents the first association of a somatic HIF2A gain-of-function mutation with PHEO and congenital polycythemia, and it alerts physicians to perform proper genetic screening in patients presenting with multiple norepinephrine-producing PHEOs and polycythemia. This report also extends the previous findings of a new syndrome of only multiple PGLs, somatostatinomas, and polycythemia to multiple PHEOs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23539726      PMCID: PMC3644612          DOI: 10.1210/jc.2013-1217

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

3.  MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.

Authors:  Nelly Burnichon; Alberto Cascón; Francesca Schiavi; Nicole Paes Morales; Iñaki Comino-Méndez; Nasséra Abermil; Lucía Inglada-Pérez; Aguirre A de Cubas; Laurence Amar; Marta Barontini; Sandra Bernaldo de Quirós; Jérôme Bertherat; Yves-Jean Bignon; Marinus J Blok; Sara Bobisse; Salud Borrego; Maurizio Castellano; Philippe Chanson; María-Dolores Chiara; Eleonora P M Corssmit; Mara Giacchè; Ronald R de Krijger; Tonino Ercolino; Xavier Girerd; Encarna B Gómez-García; Alvaro Gómez-Graña; Isabelle Guilhem; Frederik J Hes; Emiliano Honrado; Esther Korpershoek; Jacques W M Lenders; Rocío Letón; Arjen R Mensenkamp; Anna Merlo; Luigi Mori; Arnaud Murat; Peggy Pierre; Pierre-François Plouin; Tamara Prodanov; Miguel Quesada-Charneco; Nan Qin; Elena Rapizzi; Victoria Raymond; Nicole Reisch; Giovanna Roncador; Macarena Ruiz-Ferrer; Frank Schillo; Alexander P A Stegmann; Carlos Suarez; Elisa Taschin; Henri J L M Timmers; Carli M J Tops; Miguel Urioste; Felix Beuschlein; Karel Pacak; Massimo Mannelli; Patricia L M Dahia; Giuseppe Opocher; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo
Journal:  Clin Cancer Res       Date:  2012-03-27       Impact factor: 12.531

4.  A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.

Authors:  Melanie J Percy; Quan Zhao; Adrian Flores; Claire Harrison; Terence R J Lappin; Patrick H Maxwell; Mary Frances McMullin; Frank S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

5.  Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas.

Authors:  B E Baysal; J E Willett-Brozick; E C Lawrence; C M Drovdlic; S A Savul; D R McLeod; H A Yee; D E Brackmann; W H Slattery; E N Myers; R E Ferrell; W S Rubinstein
Journal:  J Med Genet       Date:  2002-03       Impact factor: 6.318

Review 6.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

7.  A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.

Authors:  Melanie J Percy; Paul W Furlow; Guy S Lucas; Xiping Li; Terence R J Lappin; Mary Frances McMullin; Frank S Lee
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

8.  Phenotypic heterogeneity of genomic disorders and rare copy-number variants.

Authors:  Santhosh Girirajan; Jill A Rosenfeld; Bradley P Coe; Sumit Parikh; Neil Friedman; Amy Goldstein; Robyn A Filipink; Juliann S McConnell; Brad Angle; Wendy S Meschino; Marjan M Nezarati; Alexander Asamoah; Kelly E Jackson; Gordon C Gowans; Judith A Martin; Erin P Carmany; David W Stockton; Rhonda E Schnur; Lynette S Penney; Donna M Martin; Salmo Raskin; Kathleen Leppig; Heidi Thiese; Rosemarie Smith; Erika Aberg; Dmitriy M Niyazov; Luis F Escobar; Dima El-Khechen; Kisha D Johnson; Robert R Lebel; Kiana Siefkas; Susie Ball; Natasha Shur; Marianne McGuire; Campbell K Brasington; J Edward Spence; Laura S Martin; Carol Clericuzio; Blake C Ballif; Lisa G Shaffer; Evan E Eichler
Journal:  N Engl J Med       Date:  2012-09-12       Impact factor: 91.245

Review 9.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.

Authors:  Brian Keith; Randall S Johnson; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

10.  A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.

Authors:  Patricia L M Dahia; Ken N Ross; Matthew E Wright; César Y Hayashida; Sandro Santagata; Marta Barontini; Andrew L Kung; Gabriela Sanso; James F Powers; Arthur S Tischler; Richard Hodin; Shannon Heitritter; Francis Moore; Robert Dluhy; Julie Ann Sosa; I Tolgay Ocal; Diana E Benn; Deborah J Marsh; Bruce G Robinson; Katherine Schneider; Judy Garber; Seth M Arum; Márta Korbonits; Ashley Grossman; Pascal Pigny; Sérgio P A Toledo; Vania Nosé; Cheng Li; Charles D Stiles
Journal:  PLoS Genet       Date:  2005-07-25       Impact factor: 5.917

View more
  24 in total

Review 1.  Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.

Authors:  Svenja Nölting; Ashley Grossman; Karel Pacak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-09-20       Impact factor: 2.949

2.  Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Authors:  David Taïeb; Anne Barlier; Chunzhang Yang; Morgane Pertuit; Aurélie Tchoghandjian; Claire Rochette; Hélène Zattara-Canoni; Dominique Figarella-Branger; Zhengping Zhuang; Karel Pacak; Philippe Metellus
Journal:  J Neurooncol       Date:  2015-10-29       Impact factor: 4.130

Review 3.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 4.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 5.  The HIF and other quandaries in VHL disease.

Authors:  D Tarade; M Ohh
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

Review 6.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

Review 7.  A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.

Authors:  Qiuli Liu; Yan Wang; Dali Tong; Gaolei Liu; Wenqiang Yuan; Jun Zhang; Jin Ye; Yao Zhang; Gang Yuan; Qingxing Feng; Dianzheng Zhang; Jun Jiang
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

8.  Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.

Authors:  Ying Pang; Garima Gupta; Abhishek Jha; Xupeng Yue; Herui Wang; Thanh-Truc Huynh; Aiguo Li; Liping Li; Eva Baker; Emily Chew; Richard A Feelders; Esther Korpershoek; Zhengping Zhuang; Chunzhang Yang; Karel Pacak
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

9.  Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.

Authors:  Roland Därr; Joan Nambuba; Jaydira Del Rivero; Ingo Janssen; Maria Merino; Milena Todorovic; Bela Balint; Ivana Jochmanova; Josef T Prchal; Ronald M Lechan; Arthur S Tischler; Vera Popovic; Dragana Miljic; Karen T Adams; F Ryan Prall; Alexander Ling; Meredith R Golomb; Michael Ferguson; Naris Nilubol; Clara C Chen; Emily Chew; David Taïeb; Constantine A Stratakis; Tito Fojo; Chunzhang Yang; Electron Kebebew; Zhengping Zhuang; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2016-09-27       Impact factor: 5.678

Review 10.  Familial pheochromocytomas and paragangliomas.

Authors:  Kathryn S King; Karel Pacak
Journal:  Mol Cell Endocrinol       Date:  2013-08-07       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.